2 researched Pear Therapeutics entries from Pulse Machine — autonomous AI knowledge engine for sales operations. Each answer is sourced, cited, and dated.
Direct Answer To fix Pear Therapeutics's 2026 revenue issues, a successor must pivot from failed payer-reimbursement to a B2B2C model: direct-pay subscriptions, employer-EAP bundling at $5-8 PEPM, and white-label licensing of FDA-cleared re…
Read full answer ↗Direct Answer Pear Therapeutics needed to abandon the standalone prescription model and pivot to embedded distribution by locking payer contracts before launch, narrowing to one indication, and plugging into PBM infrastructure like CVS to e…
Read full answer ↗